MedMira, Inc. : USAID Approves MedMira’s CE Marked Reveal HIV Test
04/04/2012| 10:04am US/Eastern
Recommend:
Halifax, Nova Scotia, April 4, 2012 - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic
technology and solutions, announced today that the Company's
most advanced rapid HIV test, Reveal HIV, has been approved
by the United States Agency for International Development
(USAID) for inclusion on its list of approved rapid HIV
tests.
Since its inception in 1986, the USAID HIV/AIDS program has
invested over $7 billion to fight this global crisis.
USAID is a key partner in the U.S. President's Emergency Plan
for AIDS Relief (PEPFAR), the largest and most diverse
HIV/AIDS prevention, care, and treatment initiative in the
world.
With this approval and listing, MedMira's CE-marked rapid HIV
tests, in addition to the previously listed FDA-approved
rapid HIV test, are eligible for procurement with funds
provided by USAID. This new approval further
strengthens the Company's global rapid HIV test product line
and serves as a strong foundation for MedMira to bring
forward its other rapid diagnostic product lines, including
Multiplo, for similar programs and approvals.
"We are very pleased with this latest approval and MedMira
will continue to expand upon its portfolio of products within
organizations such as USAID and PEPFAR in order to meet the
increasing global demand, particularly in developing
countries, for high quality rapid diagnostics," said Hermes
Chan, CEO, MedMira Inc. "With the addition of three
formats of MedMira's CE-marked rapid HIV test, projects
funded by USAID and PEPFAR will be able to select the right
format of the product for their testing initiative and
further global HIV prevention and control efforts."
Organizations purchasing Reveal HIV from the approved USAID
list can now select the format and packaging that best suits
their program needs. The various Reveal HIV product
configurations available through USAID offer customers
choice, flexibility and convenience whether their testing
program is taking place in a hospital setting, a voluntary
testing clinic, or through a mobile testing vehicle.
Chan continued, "The Reveal HIV product line satisfies the
needs of a broad range of USAID sponsored testing
programs. Resource-constrained testing programs can use
the convenient and cost-effective all-in-one package for
fingerstick, point-of-care testing while reference
laboratories and other clinical settngs can use the
veni-puncture whole blood/serum/plasma formats for batch
testing. The two laboratory formats offer customers
significantly decreased administrative costs and testing
time, a key advantage over other rapid HIV testing technology
in large scale, government screening programs."
About MedMira
MedMira is a leading developer and manufacturer of
flow-through rapid diagnostics. The company's tests provide
hospitals, labs, clinics and individuals with reliable, rapid
diagnosis for diseases such as HIV and hepatitis C in just
three minutes. The company's tests are sold under the
Reveal®, Multiplo™ and Miriad brands in global markets.
MedMira's rapid flow-through HIV test is the only one in the
world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate
offices and manufacturing facilities are located in Halifax,
Nova Scotia, Canada. For more information visit MedMira's
website at www.medmira.com.
This news release contains forward-looking statements,
which involve risk and uncertainties and reflect the
Company's current expectation regarding future events
including statements regarding possible future growth and new
business opportunities. Actual events could materially
differ from those projected herein and depend on a number of
factors including, but not limited to, changing market
conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval
process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly
filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
MedMira Contact:
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com
distributed by
|
This press release was issued by MedMira Inc. and was initially posted at http://www.medmira.com/default.asp?mn=1.85.132&sfield=content.id&search=389 . It was distributed, unedited and unaltered, by noodls on 2012-04-04 15:52:41 PM. The issuer is solely responsible for the accuracy of the information contained therein.
|
Recommend :
